Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
about
Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target TherapyEssential medicines for breast cancer in low and middle income countries.Weight change and its impact on prognosis after adjuvant TAC (docetaxel-doxorubicin-cyclophosphamide) chemotherapy in Korean women with node-positive breast cancer.
P2860
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Docetaxel for the adjuvant tre ...... a single technology appraisal.
@en
Docetaxel for the adjuvant tre ...... a single technology appraisal.
@nl
type
label
Docetaxel for the adjuvant tre ...... a single technology appraisal.
@en
Docetaxel for the adjuvant tre ...... a single technology appraisal.
@nl
prefLabel
Docetaxel for the adjuvant tre ...... a single technology appraisal.
@en
Docetaxel for the adjuvant tre ...... a single technology appraisal.
@nl
P2093
P356
P1476
Docetaxel for the adjuvant tre ...... a single technology appraisal.
@en
P2093
A Wilkinson
J Chilcott
M Lloyd Jones
P356
10.3310/HTA13SUPPL1/02
P478
13 Suppl 1
P577
2009-06-01T00:00:00Z